

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Section 316 and by adding Section 316.2 as
6 follows:

7 (720 ILCS 570/316)

8 Sec. 316. Prescription Monitoring Program.

9 (a) The Department must provide for a Prescription
10 Monitoring Program for Schedule II, III, IV, and V controlled
11 substances, except testosterone, that includes the following
12 components and requirements:

13 (1) The dispenser must transmit to the central
14 repository, in a form and manner specified by the
15 Department, the following information:

16 (A) The recipient's name and address.

17 (B) The recipient's date of birth and gender.

18 (C) The national drug code number of the
19 controlled substance dispensed.

20 (D) (Blank).

21 (E) The quantity of the controlled substance
22 dispensed and days supply.

23 (F) The dispenser's United States Drug Enforcement

1 Administration registration number.

2 (G) The prescriber's United States Drug
3 Enforcement Administration registration number.

4 (H) The dates the controlled substance
5 prescription is filled.

6 (I) The payment type used to purchase the
7 controlled substance (i.e. Medicaid, cash, third party
8 insurance).

9 (J) The patient location code (i.e. home, nursing
10 home, outpatient, etc.) for the controlled substances
11 other than those filled at a retail pharmacy.

12 (K) Any additional information that may be
13 required by the department by administrative rule,
14 including but not limited to information required for
15 compliance with the criteria for electronic reporting
16 of the American Society for Automation and Pharmacy or
17 its successor.

18 (2) The information required to be transmitted under
19 this Section must be transmitted not later than the end of
20 the business day on which a controlled substance is
21 dispensed, or at such other time as may be required by the
22 Department by administrative rule.

23 (3) A dispenser must transmit electronically, as
24 provided by Department rule, the information required to
25 be transmitted under this Section.

26 (3.5) The requirements of paragraphs (1), (2), and (3)

1 of this subsection also apply to opioid treatment programs
2 that are licensed or certified by the Department of Human
3 Services' Division of Substance Use Prevention and
4 Recovery and are authorized by the federal Drug
5 Enforcement Administration to prescribe Schedule II, III,
6 IV, or V controlled substances for the treatment of opioid
7 use disorders. Opioid treatment programs shall attempt to
8 obtain written patient consent, shall document attempts to
9 obtain the written consent, and shall not transmit
10 information without patient consent. Documentation
11 obtained under this paragraph shall not be utilized for
12 law enforcement purposes, as proscribed under 42 CFR 2, as
13 amended by 42 U.S.C. 290dd-2. Treatment of a patient shall
14 not be conditioned upon his or her written consent.

15 (4) The Department may impose a civil fine of up to
16 \$100 per day for willful failure to report controlled
17 substance dispensing to the Prescription Monitoring
18 Program. The fine shall be calculated on no more than the
19 number of days from the time the report was required to be
20 made until the time the problem was resolved, and shall be
21 payable to the Prescription Monitoring Program.

22 (a-5) Notwithstanding subsection (a), a licensed
23 veterinarian is exempt from the reporting requirements of this
24 Section. If a person who is presenting an animal for treatment
25 is suspected of fraudulently obtaining any controlled
26 substance or prescription for a controlled substance, the

1 licensed veterinarian shall report that information to the
2 local law enforcement agency.

3 (b) The Department, by rule, may include in the
4 Prescription Monitoring Program certain other select drugs
5 that are not included in Schedule II, III, IV, or V. The
6 Prescription Monitoring Program does not apply to
7 testosterone, mifepristone, misoprostol, GnRH analogues,
8 estrogen, or controlled substance prescriptions as exempted
9 under Section 313.

10 (c) The collection of data on select drugs and scheduled
11 substances by the Prescription Monitoring Program may be used
12 as a tool for addressing oversight requirements of long-term
13 care institutions as set forth by Public Act 96-1372.
14 Long-term care pharmacies shall transmit patient medication
15 profiles to the Prescription Monitoring Program monthly or
16 more frequently as established by administrative rule.

17 (d) The Department of Human Services shall appoint a
18 full-time Clinical Director of the Prescription Monitoring
19 Program.

20 (e) (Blank).

21 (f) It is the responsibility of any new, ceased, or
22 unconnected healthcare facility and its selected Electronic
23 Health Records System or Pharmacy Management System to make
24 contact with and ensure integration with the Prescription
25 Monitoring Program. As soon as practicable after the effective
26 date of this amendatory Act of the 103rd General Assembly, the

1 Department shall adopt rules requiring Electronic Health
2 Records Systems and Pharmacy Management Systems to interface,
3 by January 1, 2024, with the Prescription Monitoring Program
4 to ensure that providers have access to specific patient
5 records during the treatment of their patients. The Department
6 shall identify actions to be taken if a prescriber's
7 Electronic Health Records System and Pharmacy Management
8 Systems does not effectively interface with the Prescription
9 Monitoring Program once the Prescription Monitoring Program is
10 aware of the non-integrated connection.

11 (g) The Department, in consultation with the Prescription
12 Monitoring Program Advisory Committee, shall adopt rules
13 allowing licensed prescribers or pharmacists who have
14 registered to access the Prescription Monitoring Program to
15 authorize a licensed or non-licensed designee employed in that
16 licensed prescriber's office or a licensed designee in a
17 licensed pharmacist's pharmacy who has received training in
18 the federal Health Insurance Portability and Accountability
19 Act and 42 CFR 2 to consult the Prescription Monitoring
20 Program on their behalf. The rules shall include reasonable
21 parameters concerning a practitioner's authority to authorize
22 a designee, and the eligibility of a person to be selected as a
23 designee. In this subsection (g), "pharmacist" shall include a
24 clinical pharmacist employed by and designated by a Medicaid
25 Managed Care Organization providing services under Article V
26 of the Illinois Public Aid Code under a contract with the

1 Department of Healthcare and Family Services for the sole
2 purpose of clinical review of services provided to persons
3 covered by the entity under the contract to determine
4 compliance with subsections (a) and (b) of Section 314.5 of
5 this Act. A managed care entity pharmacist shall notify
6 prescribers of review activities.

7 (Source: P.A. 102-527, eff. 8-20-21; 102-813, eff. 5-13-22;
8 103-477, eff. 8-4-23.)

9 (720 ILCS 570/316.2 new)

10 Sec. 316.2. Information concerning testosterone. The
11 Department shall purge from the records of the Prescription
12 Monitoring Program, as established by Section 316 of this Act,
13 all existing information concerning the prescribing or
14 dispensing of testosterone, including any such information
15 contained in the central repository or database created under
16 Section 317 of this Act, on or before January 1, 2027, and
17 shall ensure that no further records concerning the
18 prescribing and dispensing of testosterone are created or
19 maintained by the Prescription Monitoring Program. The
20 Department shall update and adopt rules consistent with this
21 Section no later than January 1, 2027.

22 Section 99. Effective date. This Act takes effect upon
23 becoming law.